Credits: Canva
After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.
With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.
The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.
So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).
Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.
The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.
As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.
This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.
As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.
The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.
The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.
In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.
However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.
Credit: Canva
The new breast cancer screening guidelines released by the American College of Physicians (ACP) call for mammography screening once every two years in asymptomatic, average-risk adult females, instead of the annual recommendation.
ACP is the largest medical specialty organization in the United States with members in more than 172 countries worldwide.
The guidance statement was developed by ACP's Clinical Guidelines Committee, which defined average risk as females
While the annual mammography has long been considered the standard, in a paper published in Annals of Internal Medicine, the ACP authors explained that the changes have been made to tackle the harms caused by false positive results and the resulting psychological distress.
The false positive results can lead to "overdiagnosis, overtreatment, additional testing, and radiation exposure, and may outweigh the uncertain benefits in this population,” said the ACP.
Also read: Breast Cancer Screening: AI May Predict Tumors Before Mammograms Can Detect Them
"This is because the benefits of screening beyond age 74 are reduced or uncertain, while potential harms, such as overdiagnosis, become more likely with increasing age," it said.
"Decisions should consider potential benefits and harms, radiation exposure, availability, patient values and preferences, and cost," the ACP said, while advising against using supplemental MRI or ultrasound for screening in this population.
Breast cancer is one of the leading causes of death in 40–49-year-old women in the United States, and screening is specifically performed to prevent death from breast cancer.
Screening only women ages 50-74 every other year – as called for by ACP – may result in up to 10,000 additional, and unnecessary, breast cancer deaths in the United States each year, said the American College of Radiology (ACR) and the Society of Breast Imaging (SBI) in a joint statement.
Also read: What's The Confusion! Why Most Women Don’t Know When To Start Mammogram Screenings?
Calling the new guidelines “outdated and hyperbolic information”, the statement noted that it will cause continued confusion among women.
"Thousands more women would endure extensive surgery, mastectomies, and chemotherapy for advanced cancers than if their cancers were found early by an annual mammogram,” it said.
Current guidelines from the ACR and the SBI urge women to start annual screening at age 40.
The ACR also recommends that women have a breast cancer risk assessment by age 25. Those at higher risk for breast cancer should talk to their doctor about starting screening before age 40 and additional screening methods -- particularly those with genetic mutations or a strong family history of breast cancer.
The United States Preventive Services Task Force (USPSTF) also urges starting annual screening at age 40 to save lives.
Further, the statement also called out ACP for its failure to recommend exams beyond digital breast tomosynthesis (DBT) for screening women with dense breasts. The statement said this "is also out of step with current research, which shows the need to go beyond DBT to help find cancer in these women".
Credit: Canva
Three cases of meningitis have been reported among schoolchildren in the Weymouth area in the UK, health officials said.
According to the UK Health Security Agency (UKHSA), of the three cases, two are pupils at Budmouth Academy, Weymouth, and the third attends Wey Valley Academy. The authorities have now rolled out meningitis vaccinations to young people in the region.
The latest outbreak comes after a meningitis outbreak was reported in the Kent region in March, which affected more than 30 people, leaving one sixth-form pupil and a university student dead.
As per the UKHSA, the new cases were confirmed between 20 March and 15 April and are not linked to the deadly Kent outbreak.
The two pupils at Budmouth Academy are contacts of each other, but it is reportedly not epidemiologically linked with the Wey Valley Academy case.
The three cases in Weymouth have been confirmed as Meningitis B (MenB) and are the same sub-strain type, but a different sub-strain to the one detected recently in Kent.
Notably, all pupils in years 7 to 13 in Weymouth, Portland, and Chickerell are to be offered antibiotics and the MenB vaccination.
Close contacts of the cases have already been offered antibiotics as a precaution.
Also read: Meningitis claimed 259,000 lives globally in 2023: The Lancet
According to UKHSA deputy director Dr Beth Smout, "it is possible that we will see further cases linked to these latest cases in Weymouth".
He stated that the authorities are widening the "offer of antibiotics and vaccination" as "an additional precaution" to reduce the risk of the infection spreading.
"School pupils and staff should attend school as normal if they remain well," the official said.
Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, the meninges. While fever is not always present, it is usually considered one of the classic symptoms of meningitis.
It is important to know the varied symptoms, causes, and treatments of meningitis for early diagnosis and proper management of the disease.
Also read: Unique Symptoms Of Meningitis That Caused An Outbreak In Kent University
Smout urged everyone to be alert to the signs and symptoms of meningococcal meningitis. Common symptoms of meningitis
"If the disease is suspected, you should seek immediate medical attention as the disease can progress rapidly," Smout said.
"The most important short-term thing and the quickest way for people to protect themselves is the antibiotic.
"The vaccine offers longer-term protection. There are two doses, four to six weeks apart, and you are only protected after the second dose," the official said.
A 2026 target trial emulation has found that glucagon-like peptide, also known as GLP-1, which is used by type-2 diabetes patients, can raise the risk of suffering from erectile dysfunction. According to a report published in the European Medical Journal, the impact of GLP-1s on sexual health outcomes in diabetic men has been inconsistent and limited. Erectile dysfunction, however, has been a prominent complication affecting 50 per cent of men with type-2 diabetes over their lifetime.
For this, researchers analysed the electronic health records of men aged 18 years and above with type-2 diabetes in the US from January 2019 to September 2024. Participants were started on treatment with either dipeptidyl peptidase-4 inhibitors (DPP4i) or GLP-1, with 5,524 and 4,910 individuals, respectively. Men with a history of erectile dysfunction diagnosis or end-stage renal disease were not part of the study population. The mean age of these men was 63 years, and the average BMI was 32.8—55 per cent of participants were White, and 23 per cent were Black. GLP-1 users were younger and had a higher prevalence of obesity compared to DPP4i users.
Experts involved in the study found that the incidence of erectile dysfunction in the GLP-1 group was about 35 cases per 1,000 person-years. In the case of DPP4i users, the number dropped to 28 per 1,000 person-years. Hence, people in the GLP-1 cohort had a 26 per cent higher risk of developing erectile dysfunction over a three-year follow-up period. Results were consistent across subgroups; however, they lacked statistical significance after adjustment for negative outcomes.
Researchers noted that the findings of the target trial emulation suggest that sexual health outcomes must be considered in diabetic men, especially those dealing with type-2 diabetes and undergoing treatment with GLP-1 drugs. These findings also highlight the need for randomised trials with standardised erectile dysfunction assessments to further investigate biological pathways.
Type-2 diabetes can cause the following complications in men:
© 2024 Bennett, Coleman & Company Limited